- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
One-on-One's PUBLIC BIOTECH - Stock performance BIO International Convention Health Care biotech industry FDA economy Investment 2012 BIO International Convention patent Events PUBLIC BIOTECH - Stats IPO biotechnology Biotechnology Industry drug development BIOTECH Partnering Industry Analysis economic developmentAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Corporate
- Biofuels & Climate Change
- Biotech Blog
- Business & Investments
- Business of Biotech
- Capital Business
- Corporate
- Environmental & Industrial
- Events
- Farmer Gene
- FierceBiotech
- Food & Agriculture
- Genome Alberta
- Health
- Inside BIO Industry Analysis
- IP Watchdog
- Life Science Leader
- One-on-One Partnering
- Patent Baristas
- Patent Docs
- Patently BIOtech
- PharmTech Talk
- Public Policy
- Snapshot
- Trade Secrets Blog
Latest From Biotech Now
Why Biotech Food Labeling Is Met with Resistance
In recent weeks, there’s been a lot of new discussion around the biotech labeling debate. On May 10, the International Food Information Council (IFIC) released its latest “Consumer Perceptions of Food Technology” survey, which showed that very few Americans cite biotechnology as an information need on food labels. Earlier this month, the California Right to Know initiative announced at various rallies held around the state that it had collected the prerequisite number of signatures to Read More >
Announcing the Buzz of BIO Winner for Pipelines of Promise!
We’re very pleased to announce the Buzz of BIO Winner for the 2012 contest of the BIO International Convention. You voted for your favorites, and it was a tight, interesting race! As such, we’re pleased to introduce you to our winner for the Pipelines of Promise category. Deuteria Pharmaceuticals, Inc,. who focuses on improving the product profile of approved drugs through ‘chiral switching’, won the Pipelines of Promise category. From Dr. Sheila DeWitt, the company’s Read More >
Biosimilars Ahead, Proceed with Caution
By Richard M. Dolinar, M.D., Chairman, Alliance for Safe Biologic Medicines In today’s budget-constrained world, the goal for health care is not only to save lives but also to save money. On Friday, May 11, the Food and Drug Administration (FDA) will hold a one-day public hearing on important medicines, known as biosimilars, that are under FDA consideration to come to the United States (U.S.) and offer the opportunity to help achieve the second prong Read More >
Industry Regulatory Issues to be Highlighted at 2012 BIO International Convention
In the words of BIO’s Andrew Emmett, Managing Director, Science & Regulatory Affairs, ‘2012 is shaping up to be a momentous year for FDA reform.’ From the reauthorization of the Prescription Drug User Fee Act (PDUFA V) to modernizing and expediting the approval of new drugs and biologics, implementing the new biosimilars pathways and addressing the growing global drug shortage crisis, all eyes are on the current regulatory environment and its role in supporting innovation. Read More >
Patent-Eligible Subject Matter after Mayo v. Prometheus: Exploring the Path Forward
Patent-Eligible Subject Matter after Mayo v. Prometheus: Exploring the Path Forward is a public round-table event hosted by the Biotechnology Industry Organization and the George Washington University Law School. Guest speakers at the round-table will discuss implementation of the Prometheus decision in patent prosecution practice, in examination guidance in the United States Patent Office, and in patent litigation. Speakers will also discuss the implications of the decision on personalized medicine and possible ways forward. Speakers include: The Hon. Paul Read More >
